First, it could be applied to a broad spectrum of neoplasms that overexpress the Eag1 channel and thus become available to a large number of patients.
Most normal cells expressing Eag1 are either protected by the blood brain barrier or represent terminally differentiated cells, thereby allowing more aggressive therapeutic intervention.